Greenwich LifeSciences (GLSI) vs Vogenx (VOGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vogenx is the larger company by market cap ($259.8 million vs $222.2 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | VOGX |
|---|---|---|
| Share price | $15.14 | $17.49 |
| Market cap | $222.23M | $259.82M |
| 1-day change | -1.62% | +8.23% |
| YTD return | -26.75% | — |
| 1-year return | +37.04% | — |
| 5-year return | -59.46% | — |
| EPS (TTM) | $-1.53 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $38.41 |
| 52-week low | $7.78 | $12.95 |
| Distance from 52-week high | -55.60% | -54.46% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +276.49% | +214.47% |
| Average volume | 138.72K | 188.79K |
| Shares outstanding | 14.68M | 14.86M |
| Employees | — | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About Vogenx
VOGX stock →Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
GLSI vs VOGX FAQ
Which is bigger, Greenwich LifeSciences or Vogenx?
Vogenx (VOGX) is larger, with a market capitalization of $259.82M compared with $222.23M for Greenwich LifeSciences (GLSI).
Are Greenwich LifeSciences and Vogenx in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.